[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

2 clusters · 4 sources · 13 days · First seen · Last updated

Oxford Nanopore Technologies financial performance

Overview

Oxford Nanopore Technologies reported a narrowing of its financial losses for the first half of the year, which resulted in an increase in its share price. The DNA-sequencing company recorded revenue of £116.7m for the six months ending June 30, a 12.3% increase at constant currency.

Adjusted EBITDA loss was reduced to £22.1m, compared to £48.3m in the previous year, while the overall loss for the period fell to £48.0m from £71.8m. Growth was supported by the clinical and biopharma markets, which rose 35% and 25% respectively, though this was partially offset by a nearly 16% decline in sales in China.

Chief Executive Officer Francis Van Parys stated the company is making progress in product development and operational performance. The company aims to reach adjusted EBITDA breakeven in FY27 and positive free cash flow in FY28, with a long-term revenue goal exceeding $1bn annually. Additionally, the company recently entered a $20m cross-licensing deal with a global diagnostics firm.

Entities

University of Oxford · Durham, North Carolina · Oxford Nanopore Technologies · Oxford Biomedica

Timeline

  1. 23 days ago

    [BUSINESS] 4 sources
    Oxford Nanopore Technologies shares rise as losses narrow

    Oxford Nanopore Technologies shares rose after the company halved its adjusted EBITDA loss to £22.1m, driven by growth in clinical and biopharma markets.

  2. about 1 month ago

    [BUSINESS] 4 sources
    Oxford Biomedica shares plunge after 2026 revenue forecast cut

    Oxford Biomedica shares dropped over 24% after it cut its 2026 revenue outlook to £180‑200 million, citing delays at its Durham, NC facility and postponed client orders.

Sources

mommygearest.com · seekingalpha.com · stocktitan.net · ukinvestormagazine.co.uk